Immunome Inc (NASDAQ: IMNM) on Monday, soared 15.69% from the previous trading day, before settling in for the closing price of $19.57. Within the past 52 weeks, IMNM’s price has moved between $5.15 and $20.80.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -38.15%. The company achieved an average annual earnings per share of 55.62%. With a float of $89.23 million, this company’s outstanding shares have now reached $91.71 million.
Immunome Inc (IMNM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immunome Inc is 2.71%, while institutional ownership is 96.17%. The most recent insider transaction that took place on Jun 03 ’25, was worth 46,900. In this transaction Director of this company bought 5,000 shares at a rate of $9.38, taking the stock ownership to the 36,415 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Director bought 7,800 for $7.78, making the entire transaction worth $60,684. This insider now owns 31,415 shares in total.
Immunome Inc (IMNM) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.11 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.61) by -0.5. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.95% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Immunome Inc (IMNM) is currently performing well based on its current performance indicators. A quick ratio of 8.90 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 214.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -2.59 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
The latest stats from [Immunome Inc, IMNM] show that its last 5-days average volume of 3.44 million was superior to 1.18 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 68.10%.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 84.01%, which indicates a significant increase from 68.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.45 in the past 14 days, which was higher than the 0.97 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.03, while its 200-day Moving Average is $11.04. Now, the first resistance to watch is $24.89. This is followed by the second major resistance level at $27.13. The third major resistance level sits at $28.97. If the price goes on to break the first support level at $20.81, it is likely to go to the next support level at $18.97. The third support level lies at $16.73 if the price breaches the second support level.
Immunome Inc (NASDAQ: IMNM) Key Stats
Market capitalization of the company is 2.08 billion based on 91,710K outstanding shares. Right now, sales total 9,040 K and income totals -292,960 K. The company made 4,020 K in profit during its latest quarter, and -43,400 K in sales during its previous quarter.
